<DOC>
	<DOCNO>NCT00945399</DOCNO>
	<brief_summary>CARTIPATCH® Autologous Chondrocyte Implantation product include functional cell matrix , indicate treatment isolate osteocartilaginous lesion . The submit protocol Phase III multicentric , prospective , control randomized clinical trial , sponsor TBF Génie Tissulaire , France . The main objective protocol compare clinical improvement IKDC subjective score microfracture-treated group CARTIPATCH® chondrocyte graft-treated group , 18 month follow surgery . Several secondary objective determine . The microfracture procedure conduct one operative step , arthroscopy CARTIPATCH® procedure conduct two operative step : 1 . Arthroscopy collect cartilage ; 2 . Implantation follow arthrotomy 6 week follow arthroscopy . Both group follow rehabilitation program .</brief_summary>
	<brief_title>Comparison Microfracture Treatment CARTIPATCH® Chondrocyte Graft Treatment Femoral Condyle Lesions</brief_title>
	<detailed_description />
	<criteria>isolated femoral osteochondral lesion age 18 45 grade 3 4 lesion ( ICRS ) size 2,5 7,5cm2 lesion depth 10mm IKDC score 55 prior surgical treatment pregnancy breastfeed allergy arthrosis varus valgus angle great 6° kiss lesion affection patella excessive laxity meniscal pathology history severe chronic disease BMI &gt; 30 HIV , Hepatitis B , C , HTLV , Syphilis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>